CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte – Yahoo Finance
Proactive Investors UK |
CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte
Yahoo Finance Under the terms of the license, CRISPR Therapeutics and Casebia will obtain non-exclusive commercial-use rights to MaxCyte's cell engineering platform to develop CRISPR/Cas9-based therapies for hemoglobin-related diseases and severe combined … MaxCyte Inks License Deal With CRISPR Therapeutics And Bayer MaxCyte deal puts it at the forefront of developments in the cutting edge arena of gene editing |
